A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule ...

The FDA has approved Ekterly (sebetralstat) as the first and only oral on-demand medication for acute attacks of hereditary angioedema (HAE).

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.